Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism

• DOI: 10.4093/dmj.2023.0277
• Publication Date: 2024-04-02T23:42:18Z
• Authors: Tong Bu; Ziyan Sun; Yi Pan; Xia Deng; Guoyue Yuan
• Keywords: 0301 basic medicine; obesity; non-alcoholic fatty liver disease; Review; RC648-665; Lipid Metabolism; Atherosclerosis; glucagon-like peptide 1; Diseases of the endocrine glands. Clinical endocrinology; adipose tissue; 03 medical and health sciences; Adipose Tissue; Glucagon-Like Peptide 1; Non-alcoholic Fatty Liver Disease; lipid metabolism; Humans; Animals; Obesity

Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide hormone that is mainly expressed in the intestine and hypothalamus. In recent years, basic and clinical studies have shown that GLP-1 is closely related to lipid metabolism, and it can participate in lipid metabolism by inhibiting fat synthesis, promoting fat differentiation, enhancing cholesterol metabolism, and promoting adipose browning. GLP-1 plays a key role in the occurrence and development of metabolic diseases such as obesity, nonalcoholic fatty liver disease, and atherosclerosis by regulating lipid metabolism. It is expected to become a new target for the treatment of metabolic disorders. The effects of GLP-1 and dual agonists on lipid metabolism also provide a more complete treatment plan for metabolic diseases. This article reviews the recent research progress of GLP-1 in lipid metabolism.